Search
Sanofi SA
SNYAdd to Watchlist
43.380USD
-0.410-0.94%
Close 07-23 16:00（ET）Quotes delayed by 15 min
104.13BMarket Cap
12.06P/E TTM
More Details of Sanofi SA Company
Sanofi SA is a France-based healthcare company based in France. The Company focuses on patient needs and engages in the research, development, manufacture, and marketing of therapeutic solutions. Its three operating segments are: Pharmaceuticals, Consumer Healthcare (CHC), and Vaccines. The Pharmaceuticals includes: Immunology, Multiple Sclerosis / Neurology, Oncology, Rare Diseases, Rare Blood Disorders, Cardiovascular, Diabetes, Established Prescription Products. The Vaccines segment comprises, for all geographical territories, the commercial operations of Sanofi Pasteur, together with research, development, and production activities dedicated to vaccines. The CHC segment comprises the commercial operations for Sanofi’s Consumer Healthcare products, together with research, development and production activities dedicated to those products. The Company’s products developed in collaboration or franchise include Dupixent, Aubagio, Lemtrada, Cerezyme, Lumizyme, Jevtana, Fabrazyme.
Sanofi SA Info
Ticker SymbolSNY
Company nameSanofi SA
IPO dateJul 01, 2002
CEOHudson (Paul)
Number of employees84587
Security typeDepository Receipt
Fiscal year-endJul 01
Address46 Avenue de la Grande Armee
CityPARIS
Stock exchangeNASDAQ OMX - NASDAQ BASIC
CountryFrance
Postal code75017
Phone33153774000
Websitehttps://www.sanofi.com/
Ticker SymbolSNY
IPO dateJul 01, 2002
CEOHudson (Paul)
Company Executives of Sanofi SA
Name
Name/Position
Position
Shareholding
Change
Mr. Olivier Charmeil
Mr. Olivier Charmeil
Executive Vice President - General Medicines, Member of the Executive Committee
Executive Vice President - General Medicines, Member of the Executive Committee
--
--
Ms. Fabienne Lecorvaisier
Ms. Fabienne Lecorvaisier
Independent Director
Independent Director
--
--
Mr. Patrick Kron
Mr. Patrick Kron
Independent Director
Independent Director
--
--
Mr. Christophe Babule
Mr. Christophe Babule
Director
Director
--
--
Mr. Paul Hudson, Ph.D.
Mr. Paul Hudson, Ph.D.
Chief Executive Officer, Executive Director, Member of the Executive Committee
Chief Executive Officer, Executive Director, Member of the Executive Committee
--
--
Ms. Rachel Duan
Ms. Rachel Duan
Independent Director
Independent Director
--
--
Ms. Lise Kingo
Ms. Lise Kingo
Independent Director
Independent Director
--
--
Ms. Natalie Bickford
Ms. Natalie Bickford
Chief People Officer, Executive Vice President, Member of the Executive Committee
Chief People Officer, Executive Vice President, Member of the Executive Committee
--
--
Ms. Julie Van Ongevalle
Ms. Julie Van Ongevalle
Executive Vice President - Consumer Healthcare, Member of the Executive Committee
Executive Vice President - Consumer Healthcare, Member of the Executive Committee
--
--
Mr. Thomas Triomphe
Mr. Thomas Triomphe
Executive Vice President - Vaccines, Member of the Executive Committee
Executive Vice President - Vaccines, Member of the Executive Committee
--
--
View more
Name
Name/Position
Position
Shareholding
Change
Mr. Olivier Charmeil
Mr. Olivier Charmeil
Executive Vice President - General Medicines, Member of the Executive Committee
Executive Vice President - General Medicines, Member of the Executive Committee
--
--
Ms. Fabienne Lecorvaisier
Ms. Fabienne Lecorvaisier
Independent Director
Independent Director
--
--
Mr. Patrick Kron
Mr. Patrick Kron
Independent Director
Independent Director
--
--
Mr. Christophe Babule
Mr. Christophe Babule
Director
Director
--
--
Mr. Paul Hudson, Ph.D.
Mr. Paul Hudson, Ph.D.
Chief Executive Officer, Executive Director, Member of the Executive Committee
Chief Executive Officer, Executive Director, Member of the Executive Committee
--
--
Ms. Rachel Duan
Ms. Rachel Duan
Independent Director
Independent Director
--
--
FAQs
Who are the top five shareholders of Sanofi SA?
The top five shareholders of Sanofi SA are: Mr. Olivier Charmeil
How many institutions hold shares of Sanofi SA (SNY)?
As of 2026Q1, 1330 institutions hold shares of Sanofi SA, with a combined market value of approximately 225.52M, accounting for 9.34% of the total shares. Compared to 2025Q4, institutional shareholding has increased by -36323619.00.